TIME for a successful cancer vaccine in NSCLC?

Abstract

www.thelancet.com/oncology Vol 17 February 2016 131 leukaemia (NCT02007044). The results from this trial will be particularly important, because preclinical studies suggest negative interactions between ibrutinib and anti-CD20 monoclonal antibodies. The effi cacy of bendamustine plus rituximab versus ibrutinib plus rituximab, versus ibrutinib alone in… (More)
DOI: 10.1016/S1470-2045(15)00554-9

Topics

  • Presentations referencing similar topics